CXCR1 and prostate cancer: Taken together, these results establish the clinical relevance of the PTENLOW/CXCR1/2HIGH cluster in two distinct cohorts and, furthermore, reveal the downstream significance of this biology in locally advanced prostate cancer to adverse outcomes after both surgery and RT interventions.